BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28822769)

  • 1. Somatic mutation analysis in melanoma using targeted next generation sequencing.
    Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
    Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
    Potrony M; Badenas C; Naerhuyzen B; Aguilera P; Puig-Butille JA; Tell-Marti G; Díaz A; Carrera C; Alos L; Delahaye N; Malvehy J; Puig S
    Clin Chem Lab Med; 2016 Nov; 54(11):1733-1738. PubMed ID: 27101548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.
    McEvoy AC; Wood BA; Ardakani NM; Pereira MR; Pearce R; Cowell L; Robinson C; Grieu-Iacopetta F; Spicer AJ; Amanuel B; Ziman M; Gray ES
    J Mol Diagn; 2018 Mar; 20(2):240-252. PubMed ID: 29305225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.
    Manca A; Paliogiannis P; Colombino M; Casula M; Lissia A; Botti G; Caracò C; Ascierto PA; Sini MC; Palomba G; Pisano M; ; ; Doneddu V; Cossu A; Palmieri G;
    J Transl Med; 2019 Aug; 17(1):289. PubMed ID: 31455347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sequencing on diagnosis and treatment of malignant melanoma.
    Castiglione R; Ihle MA; Heydt C; Schultheis AM; Merkelbach-Bruse S; Mauch C; Büttner R
    Expert Rev Mol Diagn; 2016; 16(4):423-33. PubMed ID: 26822148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.
    Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D
    Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
    Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.
    Leichsenring J; Stögbauer F; Volckmar AL; Buchhalter I; Oliveira C; Kirchner M; Fröhling S; Hassel J; Enk A; Schirmacher P; Endris V; Penzel R; Stenzinger A
    Pathology; 2018 Dec; 50(7):703-710. PubMed ID: 30348504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
    Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
    J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.